Based on the earnings transcript, ChemoCentryx has made significant progress with the launch of TAVNEOS, showing promising results in terms of patient start forms, conversion rates, and reimbursement trends. The company is also expanding its pipeline and advancing its PD-L1/PD-1 checkpoint inhibitor, CCX559. The financial situation is strong, with sufficient cash and investments to support these efforts. The stock is likely to face short-term pressure due to the early stage of the launch and the impact of COVID-19, but the long-term potential is promising.

[-1]